Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 0.56 |
| ▸ | CCR2 | P41597 | 4/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462101 | 0.92 | TACR1 (0.53) | TACR1CCR2SCN5ASCN9ASLC6A4 | |
| SCHEMBL5457402 | 0.92 | TACR1 (0.53) | TACR1CCR2SLC6A4 | |
| SCHEMBL5449327 | 0.91 | TACR1 (0.52) | TACR1CCR2SCN5ASCN9ASLC6A4 | |
| SCHEMBL5457820 | 0.90 | TACR1 (0.70) | TACR1SCN5ASCN9A | |
| SCHEMBL5455442 | 0.90 | TACR1 (0.54) | TACR1 | |
| SCHEMBL5460696 | 0.89 | TACR1 (0.59) | TACR1SCN5ASCN9A | |
| SCHEMBL5184072 | 0.88 | TACR1 (0.53) | TACR1CCR2SLC6A4 | |
| SCHEMBL5449317 | 0.87 | TACR1 (0.54) | TACR1 | |
| SCHEMBL5465002 | 0.87 | TACR1 (0.53) | TACR1SLC6A4 | |
| SCHEMBL5457198 | 0.86 | TACR1 (0.51) | TACR1CCR2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | TPH1, NTSR1, HTR1D | TACR1 68/4885CCR2 2500/4885SCN5A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.